1. Bielenberg GW, Burkhardt M (1990) 5-Hydroxytryptamine1A agonist. A new therapeutic principle for stroke treatment. Stroke 21 [suppl IV]:161–163
2. Bönisch H, Trendelenburg U (1988) The mechanism of action of indirectly acting sympathomimetic amines. Handbook of Experimental Pharmacology 90/I:247–277
3. Burkard WP, Kettler R, Da Prada M, Haefely WE (1988) Neurochemical profile of the antidepressant moclobemide, a reversible type A monoamine oxidase inhibitor with minimal tyramine maker RH (eds) Neurology and neurobiology, vol 42 B. A.R. Liss, New York, pp 168–171
4. Burkard WP, Da Prada M, Keller HH, Kettler R, Haefely W (1989a) Preclinical pharmacology of moclobemide. A review of published studies. Br J Psychiatry 155 [suppl]:84–88
5. Burkard WP, Bonetti EP, Da Prada M, Martin JR, Polc P, Schaffner R, Scherschlicht R, Hefti F, Müller RKM, Wyss P-C, Haefely W (1989b) Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther 248:391–399